Patent Issued for Cells lacking B2M surface expression and methods for allogeneic administration of such cells (USPTO 12180263).

The President and Fellows of Harvard College have been issued a patent for cells lacking B2M surface expression, allowing for allogeneic administration of such cells. The patent involves genome editing tools like CRISPR to target genes in human cells, reducing the likelihood of immune responses to allogeneic transplants. The invention provides a method to create primary human cells suitable for transplantation, eliminating surface expression of MHC Class I molecules. This development has broad applicability for hematopoietic cell-based therapy and could benefit individuals with genetic disorders, infections, or cancer. [Extracted from the article]